Cas:69383-71-7 methyl 3-(dimethylcarbamoyl)benzoate manufacturer & supplier

Chemical Name:methyl 3-(dimethylcarbamoyl)benzoate

CAS.NO:69383-71-7

Synonyms:N,N-dimethylisophthalamic acid methyl ester;3-methoxycarbonyl-N,N-dimethylbenzamide

Molecular Formula:C₁₁H₁₃NO₃

Molecular Weight:207.22600

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:46.61000

Exact Mass:207.09000

LogP:1.17500

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N,N-dimethylisophthalamic acid methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-methoxycarbonyl-N,N-dimethylbenzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-methoxycarbonyl-N,N-dimethylbenzamide Use and application,N,N-dimethylisophthalamic acid methyl ester technical grade,usp/ep/jp grade.

Related News: Three more patients have been confirmed infected with coronavirus in South Korea, bringing the country’s total to 15, the South Korean Centers for Disease Control and Prevention (KCDC) announced in a press release. methyl 3-(dimethylcarbamoyl)benzoate manufacturer However, compared with the 60-70% refinement rate in developed economies such as North America, Western Europe, and Japan, China is still only equivalent to the level of the United States in the 1980s. There is still a lot of room for improvement in China’s refinement rate. period. methyl 3-(dimethylcarbamoyl)benzoate supplier However, compared with the 60-70% refinement rate in developed economies such as North America, Western Europe, and Japan, China is still only equivalent to the level of the United States in the 1980s. There is still a lot of room for improvement in China’s refinement rate. period. methyl 3-(dimethylcarbamoyl)benzoate vendor We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. methyl 3-(dimethylcarbamoyl)benzoate factory The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo.